Oxford University Press

SHERPA: Yellow

People

  1. Segal
    Segal
  2. Saltz
    Saltz
  3. Garcia Aguilar
    Garcia Aguilar
  4. Weiser
    Weiser
  5. Nash
    Nash
  6. Paty
    Paty
  7. Shia
    Shia
  8. Cercek Hanjis
    Cercek Hanjis
  9. Diaz
    Diaz
  10. Smith
    Smith

Groups

  1. Department of Medicine (25)
  2. Gastrointestinal Oncology Service (25)
  3. Solid Tumor Oncology Division (25)
  4. Surgery (9)
  5. Survivorship Research (9)
  6. Center for Pancreatic Cancer Research (8)
  7. Colorectal Surgery (8)
  8. GSK Faculty (8)
  9. Department of Pathology and Laboratory Medicine (7)
  10. Epidemiology and Biostatistics (6)
Search Within
  1. "Neil Segal"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (7)
Groups
  1. Department of Medicine (25)
  2. Gastrointestinal Oncology Service (25)
  3. Solid Tumor Oncology Division (25)
  4. Surgery (9)
  5. Survivorship Research (9)
  6. Center for Pancreatic Cancer Research (8)

More Groups

People
  1. Neil Segal (25)
  2. Leonard Saltz (9)
  3. Andrea Cercek Hanjis (8)
  4. Julio Garcia Aguilar (7)
  5. Martin Weiser (7)
  6. Rona Yaeger (7)

More People

Years
  1. 2024 (3)
  2. 2022 (2)
  3. 2021 (4)
  4. 2019 (2)
  5. 2018 (4)
  6. 2017 (3)

More Years

Publications
  1. Annals of Oncology (21)
  2. JNCI: Journal of the National Cancer Institute (2)
  3. British Journal of Surgery (1)
  4. JNCI Cancer Spectrum (1)

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy
    Journal Article

    Bercz, A.; Park, B. K.; Pappou, E.; Nemirovsky, D.; Sarkar, R.; Yamner, M.; Omer, D.; Verheij, F. S.; Alvarez, J.; Atri, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial
    Journal Article

    Williams, H.; Yuval, J. B.; Verheij, F. S.; Miranda, J.; Lin, S. T.; Omer, D. M.; Qin, L. X.; Gollub, M. J.; Kim, T. H.; Garcia-Aguilar, J.; more...
    British Journal of Surgery (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
    Journal Article

    Ambrosini, M.; Rousseau, B.; Manca, P.; Artz, O.; Marabelle, A.; André, T.; Maddalena, G.; Mazzoli, G.; Intini, R.; Cohen, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)
    Meeting Abstract

    Kasper, S.; Segal, N. H.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; Amirouchene Angelozzi, N.; Amirouchene da Silva, A. P.; St-Pierre, A.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study (daNIS-3) of the antieTGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer
    Meeting Abstract

    Segal, N.; Rivera, F.; Tournigand, C.; Kasper, S.; Chen, Y.; Deshpande, P.; Messmann, R.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A comprehensive comparison of early-onset and average-onset colorectal cancers
    Journal Article

    Cercek, A.; Chatila, W. K.; Yaeger, R.; Walch, H.; Dos Santos Fernandes, G.; Krishnan, A.; Palmaira, L.; Maio, A.; Kemel, Y.; Srinivasan, P.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Phase I dose escalation of IMC-C103C, a CD3xMAGE-A4 T-cell receptor (TCR) bispecific protein
    Meeting Abstract

    Davar, D.; Sweis, R. F.; Blumenschein, G. Jr; Gutierrez, R.; Melero, I.; Chen, H. A.; Thistlethwaite, F.; Moore, K. N.; Segal, N. H.; Garralda, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection
    Meeting Abstract

    Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data
    Meeting Abstract

    Li, C.; Ferro, A.; Mhatre, S.; Lu, D.; Lawrance, M.; Li, S.; Allen, S.; Desai, J.; Fakih, M.; Kim, T.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Bendell, J.; Lieu, C.; Raghav, K. P. S.; Argilés, G.; Cubillo, A.; Qu, X.; Yan, Y.; Merchant, M.; Zeuner, H.; Gallo, J. D.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save